Panel discussion at Bio conference 2022 entitled: Why the FDA will bet more on in silico simulations to trigger better success rates for NDAs. The session was moderated by Colin Hill and showcased recent examples in digital, AI, and in-silico models that highlight this new reality and the real potential to decrease the timelines around clinical trials, and ultimately improve patient care.
- Andrea de Souza, AVP Global Head, Data Sciences and Engineering, Eli Lilly and Company
- Steffan Ho, MD, PhD, VP and Head of Translational Oncology, Pfizer Global Product Development
- Roychoudhury, PhD, Program Strategy Leader, Gilead Sciences
- John Quackenbush, Chair, Department of Biostatistics and Professor, Computational Biology, Harvard T.H. Chan School of Public Health